364 related articles for article (PubMed ID: 37578235)
1. A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases.
Leonard RA; Rao VN; Bartlett A; Froggatt HM; Luftig MA; Heaton BE; Heaton NS
J Virol; 2023 Aug; 97(8):e0059723. PubMed ID: 37578235
[TBL] [Abstract][Full Text] [Related]
2. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
3. Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease Inhibitors.
Jiao Z; Yan Y; Chen Y; Wang G; Wang X; Li L; Yang M; Hu X; Guo Y; Shi Y; Peng G
J Virol; 2022 Sep; 96(17):e0090722. PubMed ID: 36000844
[TBL] [Abstract][Full Text] [Related]
4. Genetic Surveillance of SARS-CoV-2 M
Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
[TBL] [Abstract][Full Text] [Related]
5. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
7. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
8. Antivirals for Broader Coverage against Human Coronaviruses.
Outteridge M; Nunn CM; Devine K; Patel B; McLean GR
Viruses; 2024 Jan; 16(1):. PubMed ID: 38275966
[TBL] [Abstract][Full Text] [Related]
9. Improved fluorescence-based assay for rapid screening and evaluation of SARS-CoV-2 main protease inhibitors.
Zhang R; Yan H; Zhou J; Yan G; Liu X; Shang C; Chen Y
J Med Virol; 2024 Mar; 96(3):e29498. PubMed ID: 38436148
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.
Tan B; Joyce R; Tan H; Hu Y; Wang J
Acc Chem Res; 2023 Jan; 56(2):157-168. PubMed ID: 36580641
[TBL] [Abstract][Full Text] [Related]
11. Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development.
Zhu W; Shyr Z; Lo DC; Zheng W
J Pharmacol Exp Ther; 2021 Aug; 378(2):166-172. PubMed ID: 33972366
[TBL] [Abstract][Full Text] [Related]
12. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR
mBio; 2018 Mar; 9(2):. PubMed ID: 29511076
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of
Tong X; Keung W; Arnold LD; Stevens LJ; Pruijssers AJ; Kook S; Lopatin U; Denison M; Kwong AD
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0084023. PubMed ID: 37800975
[TBL] [Abstract][Full Text] [Related]
14. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
15. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
[TBL] [Abstract][Full Text] [Related]
16. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
17. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
[TBL] [Abstract][Full Text] [Related]
18. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
[TBL] [Abstract][Full Text] [Related]
19. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
20. Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M
Moghadasi SA; Esler MA; Otsuka Y; Becker JT; Moraes SN; Anderson CB; Chamakuri S; Belica C; Wick C; Harki DA; Young DW; Scampavia L; Spicer TP; Shi K; Aihara H; Brown WL; Harris RS
mBio; 2022 Jun; 13(3):e0078422. PubMed ID: 35471084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
